Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Oppenheimer 28th Annual Healthcare Conference 2018

27 slides from Synergy Pharmaceuticals's conference presentation, Mar 20, 2018

  1. Slide 1: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subjec

  2. Slide 2: Key Highlights

    KEY HIGHLIGHTS • • Developing and commercializing novel gastrointestinal (GI) therapies Launching our first product, Trulance®, in the U.S. for the treatment of adults with Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C) OUR FOCUS • Proprietary uroguanyli

  3. Slide 3: CIC and IBS-C Represent a Significant Medical and Social Burden

    CIC AND IBS-C REPRESENT A SIGNIFICANT MEDICAL AND SOCIAL BURDEN at all satisfied with their care4 1. Suares NC, Ford AC. Am J Gastroenterology. 2011;106(9):1582-1591; quiz 1581, 1592. 2. Doshi JA et al. J Manag Care Spec Pharm. 2014;20(4):382-390. 3. Saito YA et al. Am J Gastroenterology. 2002;97(8)

  4. Slide 4: BURDEN-CIC and BURDEN-IBS-C: Studies of Patient and HCP Perspectives

    BURDEN–CIC AND BURDEN–IBS-C: 2 ROBUST STUDIES OF PATIENT AND HCP PERSPECTIVES ON LIVING WITH AND MANAGING CIC AND IBS-C 1,2 The BURDEN designed to: Better Understand and Recognize Disconnects, Studies were Study Design: • • Peer-reviewed design, IRB approved BURDEN-CIC1: >1200 patients and >325 HCPs

  5. Slide 5: Patients Were Not Satisfied with Current Options

    PATIENTS WERE NOT SATISFIED* WITH CURRENT OPTIONS1,2 CHRONIC PRESCRIPTION† TREATMENT Not Satisfied For patients not completely satisfied, top reasons were efficacy 59% of CIC patients and tolerability 66% of IBS-C patients †Linzess®/Amitiza® *Among chronic Rx patients stating not satisfied or not co

  6. Slide 6: ~80% of HCPs Surveyed Not Satisfied with Current Rx Treatments

    ~80% OF HCPs SURVEYED WERE NOT SATISFIED* WITH ALL CURRENT RX TREATMENTS FOR EITHER CIC OR Top rated challenges for HCPs include efficacy, compliance, and treatment-related diarrhea1,2 Compliance IBS-C1,2 IBS-C1 CIC2 58 Inadequate Response 55 55 Diarrhea 41 Lack of Options 40 Side Effects Other Than

  7. Slide 7: Still an Untapped US Market Opportunity

    STILL AN UNTAPPED US MARKET OPPORTUNITY ~ 45MM U.S. Adults With CIC / IBS-C Growth Drivers • • • Increasing awareness of “gut health” Aging population 70% of patients dissatisfied with OTC treatment2 Growing education of health care professionals and consumers – HCP promotional efforts – Direct to c

  8. Slide 8: 2017 Marked by Solid Launch Execution

    2017 MARKED BY SOLID LAUNCH EXECUTION – LAYING THE FOUNDATION FOR FUTURE SUCCESS • Drove strong customer demand with TRx volume up 70% on average month-over-month • Established strong base with top gastroenterologists key for fueling future growth • Activated the Rx-ready patient with almost half of

  9. Slide 9: Trulance Total Prescription Volume Grew Consistently in 2017

    TRULANCE TOTAL PRESCRIPTION VOLUME GREW CONSISTENTLY IN 2017 Monthly TRx (IQVIA) Monthly Normalized / Extended Unit TRx 16000 15321 14000 12000 10000 8000 6000 4000 2000 0 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Source: IQVIA, Mar. – Dec. 2017 Note: Trulance launched Ma

  10. Slide 10: Trulance Prescriber Base Showed Steady Growth

    TRULANCE PRESCRIBER BASE SHOWED STEADY GROWTH 9,644 10,000 8,868 7,974 8,000 7,043 6,121 6,000 4,949 3,768 4,000 2,427 2,000 1,145 257 0 Source: IQVIA, Mar. – Dec. 2017 Note: Trulance launched March 20, 2017 11 Oppenheimer 28th Annual Healthcare Conference I March 20, 2018 Cumulative Trulance Prescr

  11. Slide 11: Trulance Outperformed Launch Penetration of High Decile Writers vs. Analogs

    TRULANCE OUTPERFORMED LAUNCH PENETRATION OF HIGH DECILE WRITERS VS. SIMILAR LAUNCH ANALOGS Analog Penetration Trulance Penetration 80% 70% 60% 50% 40% 30% 20% 10% 0% 10 9 Market Decile 8 Source: IQVIA, Mar. – Dec. 2017 12 Oppenheimer 28th Annual Healthcare Conference I March 20, 2018 % Penetration 7

  12. Slide 12: Trulance Growth Came from Patients New to Branded Rx Treatments

    SIGNIFICANT AMOUNT OF TRULANCE GROWTH IN 2017 CAME FROM PATIENTS NEW TO BRANDED PRESCRIPTION TREATMENTS Trulance NRx Breakdown • Nearly 50% of Trulance NRx were new branded Rx therapy starts 43% of Trulance patients have Add on 8% • converted from other Rx treatments Sw h To Therapy Starts 49% Sourc

  13. Slide 13: Trulance Demand Drove Solid Revenue Growth in 2017

    TRULANCE DEMAND DROVE SOLID REVENUE GROWTH IN 2017 Trulance Net Sales $10 $9 $8 $7 $6 $5 $4 $3 $2 $1 $0 1Q 2017 2Q 2017 3Q 2017 4Q 2017 * Includes $1.9 of sales previously recorded as deferred revenue Source: Company data; Note: Trulance Launched March 20, 2017 Oppenheimer 28th Annual Healthcare Con

  14. Slide 14: 2018 Key Business Priorities

    2018 KEY BUSINESS PRIORITIES • OPTIMIZING THE VALUE OF TRULANCE • ENSURING A STRONG FINANCIAL FOUNDATION • EXPLORING ALL STRATEGIC AND BUSINESS DEVELOPMENT OPPORTUNITIES 15 Oppenheimer 28th Annual Healthcare Conference I March 20, 2018

  15. Slide 15: Optimizing the Value of Trulance

    OPTIMIZING THE VALUE OF TRULANCE • Continuing to grow market share in CIC • Accelerating uptake with new IBS-C indication • Leveraging strong foundation established with healthcare broaden prescriber base providers to • Continuing to educate and activate the Rx ready patient • Pulling-through market

  16. Slide 16: Trulance Product Profile

    TRULANCE PRODUCT PROFILE Pharmacology • First and only uroguanylin analog treatment now FDA approved in CIC and IBS-C Efficacy • Evaluated in the largest Phase 3 CIC and IBS-C trials to-date Safety / Tolerability • Diarrhea was most common adverse event (<5%) Dosing • Once a day, any time of the day

  17. Slide 17: Trulance Provides Simple Dosing with Convenient Packaging

    TRULANCE PROVIDES SIMPLE PACKAGING DOSING WITH CONVENIENT Simple Dosing & Administration Once a day Any time of day Convenient & Innovative Packaging With or without food Source: Company Data 18 Oppenheimer 28th Annual Healthcare Conference I March 20, 2018

  18. Slide 18: Key Customers and Core Strategies

    KEY CUSTOMERS AND CORE STRATEGIES Drive Awareness of Trulance and Trial and Adoption Stimulate HCPs Activate and Support the Rx Ready Patient PATIENTS Ensure Access PAYERS 19 Oppenheimer 28th Annual Healthcare Conference I March 20, 2018 Core Strategies

  19. Slide 19: Educating HCPs with Personal Selling and Peer-to-Peer Marketing

    EDUCATING HCPs WITH STRONG PERSONAL SELLING, NON-PERSONAL PROMOTION AND PEER-TO-PEER MARKETING • Highly experienced sales force continuing to educate top prescribers on Trulance for CIC and now IBS-C HCPs • Drive Awareness of Trulance and Stimulate Trial / Adoption • Distributed nearly half a millio

  20. Slide 20: Direct-to-Patient Plan Activating the Rx Ready Patient

    DIRECT-TO-PATIENT PLAN FOCUSED ON ACTIVATING AND SUPPORTING THE RX READY PATIENT • Trulance Branded Campaign PATIENTS – – – – Point-of-Care Promotion: ~20,000 offices Web Sponsorships/Display Ads: >215,500,000 impressions Search Marketing: >20,400,000 impressions Trulance.com (consumer site): > 1,20

  21. Slide 21: Payer Strategy Focused on Ensuring Broad Access

    PAYER STRATEGY FOCUSED ON ENSURING BROAD ACCESS PAYERS • Optimizing current coverage by pulling through market access wins Focused on improving national Commercial and Medicare Part D coverage Identifying key regional Commercial and Medicaid plans to expand coverage and coordinate sales activities t

  22. Slide 22: Trulance Weekly TRx Volume

    TRULANCE WEEKLY TRX VOLUME TRX VOLUME VS. EXTENDED UNIT Weekly TRx (IQVIA) Weekly Normalized / Extended Unit TRx 4,000 3733 3,500 2894 3,000 2,500 2,000 January 1,500 1,000 500 0 Source: IQVIA, Mar. 2017 – Mar. 9, 2018 Note: Trulance launched March 20, 2017 23 Oppenheimer 28th Annual Healthcare Conf

  23. Slide 23: Ensuring a Strong Financial Foundation

    ENSURING A STRONG FINANCIAL FOUNDATION • Achieving cost efficiencies and maintaining disciplined expense management – – Reduced Q4 2017 OPEX by 13% from Q3 2017 Projecting total OPEX in range of $175-185 million for 2018, a reduction of 10-15% from 2017 • Prioritizing key commercial investments in h

  24. Slide 24: Exploring All Strategic and Business Development Opportunities

    EXPLORING ALL STRATEGIC AND BUSINESS DEVELOPMENT OPPORTUNITIES • Maximizing Trulance through partnerships in U.S. and ex-U.S. – Completed Canadian licensing deal • Continuing to evaluate opportunities to advance dolcanatide development • Actively exploring opportunities that leverage our commercial

  25. Slide 25: 2018 Key Business Priorities

    2018 KEY BUSINESS PRIORITIES • OPTIMIZING THE VALUE OF TRULANCE – – – Continuing to grow market share in CIC Accelerating Trulance uptake with new IBS-C indication and newly integrated field force Pulling-through market access wins and expanding coverage • ENSURING STRONG FINANCIAL FOUNDATION – – –

  26. Slide 26: Oppenheimer 28th Annual Healthcare Conference

    OPPENHEIMER 28TH ANNUAL HEALTHCARE CONFERENCE March 20, 2018

  27. Slide 27: Synergy Pharmaceuticals

    SYNERGY PHARMACEUTICALS March 20, 2018

Synergy Pharmaceuticals — Oppenheimer 28th Annual Healthcare Conference 2018 on 6ix